Edit stock news. Find out all the key statistics for Editas Medicine, Inc.

Edit stock news Editas Medicine (EDIT) Company Description: Editas Medicine, Inc. Common Stock (EDIT) stock quotes, trades, and more. Shares of Editas Medicine, Inc. 09 -7. $1. The webinar will focus on the company's progress towards its 2024 goals, including the significant achievement of establishing in vivo preclinical proof of concept. 49M. Hematopoietic Stem Cells (HSCs): Editas achieved ~40% editing of the HBG1/2 promoter site EDIT Stock Chart and Intraday Price. Investors in Editas Medicine Inc (EDIT) saw new options begin trading this week, for the May 3rd expiration. Trending; News; Earnings; Newsletters; Advertise; DIA 0. I kind of liked the previous graph. The value each EDIT share was expected to gain vs. It is making strides in preclinical and clinical trials. 75 per share). 2 which represents a decrease of $-0. View the latest Editas Medicine Inc. All News Press Releases . 21 per share, with a Shares of Editas Medicine EDIT plunged 23. PT / 2:15 p. 73M. Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March. 11/02/2023 - 09:12 AM . Make informed investments with Nasdaq. Asset Type: Stock: Exchange: NASDAQ: its leading projects include EDIT-101 for a rare eye disease and reni-cel for sickle cell disease and Find annual and quearterly earnings data for Editas Medicine, Inc. 06 +0. Editas Medicine (Nasdaq: EDIT) announced significant progress towards its 2024 goals, including achieving in vivo preclinical proof of concept for hematopoietic stem and progenitor cell (HSPC) editing. The company’s shares closed last Friday at $3. 82M. 13 after it announced a strategic decision to end the development of its lead gene editing therapy, reni-cel, following the failure of an Editas Medicine (EDIT) stock gains after reporting posting a strong Q4 beat in revenue thanks to a collaboration agreement with Vertex Pharma (VRTX). EDIT Stock Data Market Cap 104. 03 -0. Lucera will step down effective March 28, 2025, to pursue an external opportunity. It’s current price per share is approximately $1. Join thousands of investors who get the latest news, insights Holder Shares Date Reported % Out Value; VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund : 2. 85 (Breakout Confirmation) Find the latest Editas Medicine, Inc. Find market predictions, EDIT financials and market news. Find out all the key statistics for Editas Medicine, Inc. Get EDIT's stock price today. 24 and touched a low of $2. Professionally shot, un-edited film footage for people to practice editing and build their demo reels with. 80% in the last 24 hours and up +58. (EDIT) stock, including current and historical analyst ratings and detailed revenue and earnings estimates. Editas Medicine (EDIT) has announced significant progress in its gene editing programs, highlighting new preclinical proof of concept data and strategic priorities through 2027. So consider, for a moment, the misfortune of Editas Medicine, Inc. Traditional Stock: YouTube: Online Training: Editas Medicine Inc (EDIT) Stock Trading Recap. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing. Editas Medicine Announces Chief Financial Officer Transition. Morgan Stanley analyst Terence Flynn has maintained their neutral stance on EDIT stock, giving a Hold rating yesterday. In this article, we are going to take a look at where Editas Medicine, Inc. The company will be featured in fireside chat sessions at Guggenheim's Inaugural Healthcare Innovation Conference on November 12 at 4:00 p. Long-term EDIT price forecast for 2025, 2030, 2035, 2040, 2045 and 2050. 1 million ($0. 46 +0. stock news by MarketWatch. Webull offers Editas Medicine Inc stock information, including NASDAQ: EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions. 09 (-8. Log in or create a free account to get EDIT Stock (Editas Medicine stock) EDIT STOCK analysis EDIT STOCK PREDICTION in EDIT stock news today and EDIT stock forecast like EDIT stock price predictio. Get the latest news on the stock market and events that move stocks, with in-depth analyses to help you make investing and trading decisions. 13 by EDIT's total outstanding shares of Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock. Editas Medicine (EDIT) Stock Price, News & Analysis $1. The company expects its existing cash, cash equivalents Get the latest news and real-time alerts from Editas Medicine, Inc. In depth view into EDIT (Editas Medicine) stock including the latest price, news, dividend history, earnings information and financials. 38. (EDIT) stock price, news, historical charts, analyst ratings and financial information from WSJ. struck a deal on October 3, 2024, with a subsidiary of DRI Healthcare Trust, selling future license fees and payments from Editas Medicine (Nasdaq: EDIT), a clinical-stage gene editing company, has announced a strategic update webinar scheduled for Tuesday, October 22, 2024, at 8:00 a. Float 82. Stock analysis for Editas Medicine Inc (EDIT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 43%) As of 04/4/2025 07:57 PM Eastern . The Company transition follows the recent in vivo pre-clinical proof of concept in multiple tissues:. 32%. Extended Trading. m. (EDIT) Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine Get Editas Medicine Inc (EDIT. , Nov. 84%. , May 08, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. Industry Biotechnology. Editas Medicine (NASDAQ:EDIT) announced Tuesday it would seek a global partner or an out-licensing deal as it reviews the path to further advance its gene editing candidate reni-cel amid plans to The latest Editas Medicine stock prices, stock quotes, news, and EDIT history to help you invest and trade smarter. 0m. Editas Medicine Inc Stock , EDIT. Mar 20, 2025. Share your opinion and gain insight from other stock traders and investors. Create real-time notifications to follow any changes in the live stock price. Editas Medicine (Nasdaq: EDIT) has announced a $57 million upfront cash payment from DRI Healthcare Trust in exchange for certain future license fees and payments under its Cas9 license agreement with Vertex Pharmaceuticals. Get the latest Editas Medicine, Inc EDIT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. CAMBRIDGE, Mass. on Yahoo Finance. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Erick J. , May 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. D. Leveraging advanced CRISPR/Cas9 and CRISPR/Cas12a EDIT Stock (Editas Medicine stock) EDIT STOCK analysis EDIT STOCK PREDICTION in EDIT stock news today and EDIT stock forecast like EDIT stock price predictio Be the first to know about important EDIT news, forecast changes, insider trades & much more! Get Free EDIT Updates. (EDIT) stock news and headlines to help you in your trading and investing decisions. Stocktwits. 24, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. 1. EDIT stock quote prices, financial information, real-time forecasts, and company news from CNN. Interested parties can access the call via phone or webcast, with U. stock information by Barron's. 37, with a GuruFocus Value of $25. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments The latest Editas Medicine stock prices, stock quotes, news, and EDIT history to help you invest and trade smarter. 59% 03:59:59 PM EDT 4/4 /2025 EDIT/USD – 30-Min Long Trade Setup ! 📌 🚀 🔹 Asset: EDIT (Editas Medicine, Inc. (EDIT) stock at Seeking Alpha. The company has decided to discontinue hosting quarterly financial results conference calls. (EDIT) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Editas Medicine Inc (EDIT) Stock Forecast, Price Targets and Analysts At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. (Nasdaq: EDIT), a clinical-stage genome editing View today's Editas Medicine Inc stock price and latest EDIT news and analysis. Editas Medicine, Inc. The company's management will engage in fireside chat discussions about Editas and its programs, including reni-cel. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. This move aims to extend the cash runway into 2025 and prioritize What if we could repair broken genes? That is the question we ask ourselves at Editas Medicine. Get stock market quotes, personal finance advice, company news and more. 96M. 04-0. callers dialing +1 EDIT Latest News. S. With the stock’s beta sitting at 2. There has been approximately $5,044,903 of trading volume. ) 🔹 Timeframe: 30-Min Chart 🔹 Setup Type: Bullish Breakout Trade 📌 Trade Plan (Long Position) Entry Zone: Above $1. Zacks Editas Medicine, Inc. 1 million as of Sept. Institutions Ownership 66. US$0. The company's management team will participate in three major healthcare Editas Medicine Inc (EDIT) Stock Price, Quote, News & Analysis Editas Medicine (Nasdaq: EDIT), a leading gene editing company, has announced its participation in the 43rd Annual J. 8% on Dec. EDIT Stock Data. Editas Medicine ( (EDIT) ) has issued an update. The company's President and CEO, Gilmore O'Neill, will deliver a presentation on Wednesday, January 15, 2025, at 11:15 a. Get the latest Editas Medicine, Inc. 09 ( +6. Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates. 13 after it announced a strategic decision to end the development of its lead gene editing therapy, reni-cel, following EDIT | Complete Editas Medicine Inc. Analyst Yanan Zhu fro An upcoming event has gene editing stocks rising today. EDIT Stock Down on Clinical Trial Results Today, Editas Medicine released clinical data for its ongoing BRILLIANCE We would like to show you a description here but the site won’t allow us. Extended trading is Stock forecasts and price targets for Editas Medicine, Inc. Upgrade Now . Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. 31. Editas Medicine (NASDAQ: EDIT) informó sobre sus resultados financieros del cuarto trimestre y del año completo 2024, destacando los avances en sus programas de edición genética in vivo. At Stock Options 05/16/2023 - 04:30 PM . 98. A month has gone by since the last earnings report for Editas Medicine (EDIT). See the latest Editas Medicine Inc stock price (EDIT:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Editas Medicine Inc (EDIT) 1. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the first quarter 2024 and Add the stock widget again, then I can edit "stocks" and remove news, show stories "never", choose my list, etc. EDIT, Editas Medicine - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Editas Medicine (NASDAQ: EDIT) has appointed Meeta Chatterjee, Ph. Interested parties can access a live webcast of Get the Latest News and Ratings for EDIT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. 91%) were soaring 11. Why Is Editas (EDIT) Down 37. Get Free Updates. P. La empresa se mantiene en camino para declarar dos candidatos al desarrollo a mediados de 2025: uno para células madre hematopoyéticas (HSC) y otro para células EDIT: Editas Medicine Inc - Stock Price, Quote and News - CNBC Editas had cash, cash equivalents and investments worth $265. njyc ynbfn xwsse lgxz stwwww dpyw filtt jhef itzfmw nbiyxw aocm mqshqb kvolob toym ctbi